Author

Sue Erickson-Viitanen

Observed names: S. Erickson-Viitanen, Sue Erickson‐Viitanen

Institution: Incyte (United States)

Observed institution: Incyte (United States)

OpenAlex ID: A5078049017

The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).

2008 · Srdan Verstovsek, Hagop M. Kantarjian, et al. · Blood · 46

Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I

2011 · Srdan Verstovsek, Ruben A. Mesa, et al. · Blood · 23

Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50–100 × 109/L): A Comparison to Patients with Normal or High Starting Platelet Counts

2012 · Moshe Talpaz, Ronald Paquette, et al. · Blood · 14

A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

2018 · Naval G. Daver, Marina Kremyanskaya, et al. · Blood · 13

Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study

2022 · Abdulraheem Yacoub, Uma Borate, et al. · Blood · 10

Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF,

2011 · Ruben A. Mesa, Jason Gotlib, et al. · Blood · 10

Abstract CT162: Addition of parsaclisib (INCB050465), a PI3Kδ inhibitor, in patients with suboptimal response to ruxolitinib: A phase 2 study in patients with myelofibrosis

2021 · Abdulraheem Yacoub, Eunice S. Wang, et al. · Cancer Research · 9

MPN-127: Add-On Parsaclisib (a PI3K5 Inhibitor) in Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib: Interim Analysis from a Phase 2 Study

2021 · Abdulraheem Yacoub, Uma Borate, et al. · Clinical Lymphoma Myeloma & Leukemia · 8

Sustained‐release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis

2018 · Srdan Verstovsek, Swamy Yeleswaram, et al. · Hematological Oncology · 8

MPN-075 Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Low Versus Higher Baseline Platelet Counts: A Subgroup Analysis of Data From a Phase 2 Study

2022 · Abdulraheem Yacoub, Uma Borate, et al. · Clinical Lymphoma Myeloma & Leukemia · 3

Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

2021 · Abdulraheem Yacoub, Uma Borate, et al. · Blood · 2

Clinical Burden and Progression of Myelofibrosis in a Controlled Study Population of Placebo-Treated Patients (COMFORT-I)

2011 · Srdan Verstovsek, Ruben A. Mesa, et al. · Blood · 2

Abstract CT541: Efficacy and safety of parsaclisib-ruxolitinib combination therapy in myelofibrosis patients (Pts) with low vs higher baseline platelet count (PC): A subgroup analysis of data from a phase 2 study

2022 · Abdulraheem Yacoub, Uma Borate, et al. · Cancer Research · 1

A model to estimate spleen volume from palpated spleen length in patients with myelofibrosis

2026 · Albert Assad, Sue Erickson-Viitanen, et al. · Annals of Hematology

Poster: MPN-075 Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Low Versus Higher Baseline Platelet Counts: A Subgroup Analysis of Data From a Phase 2 Study

2022 · Abdulraheem Yacoub, Uma Borate, et al. · Clinical Lymphoma Myeloma & Leukemia

Poster: MPN-127: Add-On Parsaclisib (a PI3Kδ Inhibitor) in Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib: Interim Analysis from a Phase 2 Study

2021 · Abdulraheem Yacoub, Uma Borate, et al. · Clinical Lymphoma Myeloma & Leukemia

Abstract CT252: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment-Naïve Myelofibrosis

2021 · Abdulraheem Yacoub, Sue Erickson-Viitanen, et al. · Cancer Research

PCN109 Progressive Worsening of Patient-Reported Outcomes in Untreated Patients With Myelofibrosis

2012 · R. Mesa, A. Shields, et al. · Value in Health

Works count: 18

Citation count: 149

H-index: 8

I10-index: 6